

? d s

Set	Items	Description
S1	9384424	S CANCER OR TUMOR OR TUMOUR OR MALIGNAN?
S2	3910277	S ANTIBOD?
S3	1034	S HM124 OR HM1(1N)24 OR BST2 OR BST(1N)2
S4	4985	S AU=KAWAI
S5	1179	S AU=MIHARA
S6	25	S AU=KOISHIHARA
S7	162	S S2(3N)S3
S8	119	RD (unique items)
S9	95	S S8 AND S1
S10	95	RD (unique items)
S11	4	S S4 AND S3
S12	1	S S5 AND S3
S13	15	S S6 AND S3
S14	17	S S11 OR S12 OR S13
S15	17	RD (unique items)
S16	1	S S15 NOT S10

? show files

[File 5] **Biosis Previews(R)** 1926-2007/Jul W1

(c) 2007 The Thomson Corporation. All rights reserved.

**File 5: BIOSIS has been enhanced with archival data. Please see HELP NEWS 5 for information.*

[File 34] **SciSearch(R) Cited Ref Sci** 1990-2007/Jul W2

(c) 2007 The Thomson Corp. All rights reserved.

[File 35] **Dissertation Abs Online** 1861-2007/Jun

(c) 2007 ProQuest Info&Learning. All rights reserved.

[File 45] **EMCare** 2007/Jun W4

(c) 2007 Elsevier B.V. All rights reserved.

[File 65] **Inside Conferences** 1993-2007/Jul 03

(c) 2007 BLDSC all rts. reserv. All rights reserved.

[File 71] **ELSEVIER BIOBASE** 1994-2007/Jul W1

(c) 2007 Elsevier B.V. All rights reserved.

[File 73] **EMBASE** 1974-2007/Jun 26

(c) 2007 Elsevier B.V. All rights reserved.

[File 91] **MANTIS(TM)** 1880-2007/Apr

2001 (c) Action Potential. All rights reserved.

[File 98] **General Sci Abs** 1984-2007/Jun

(c) 2007 The HW Wilson Co. All rights reserved.

[File 144] **Pascal** 1973-2007/Jun W4

(c) 2007 INIST/CNRS. All rights reserved.

[File 149] **TGG Health&Wellness DB(SM)** 1976-2007/Jun W4
(c) 2007 The Gale Group. All rights reserved.

[File 155] **MEDLINE(R)** 1950-2007/Jun 29
(c) format only 2007 Dialog. All rights reserved.

[File 156] **ToxFile** 1965-2007/Jun W4
(c) format only 2007 Dialog. All rights reserved.

[File 159] **Cancerlit** 1975-2002/Oct
(c) format only 2002 Dialog. All rights reserved.
**File 159: Cancerlit is no longer updating. Please see HELP NEWS159.*

[File 162] **Global Health** 1983-2007/May
(c) 2007 CAB International. All rights reserved.

[File 164] **Allied & Complementary Medicine** 1984-2007/Jun
(c) 2007 BLHCIS. All rights reserved.

[File 172] **EMBASE Alert** 2007/Jun 26
(c) 2007 Elsevier B.V. All rights reserved.

[File 369] **New Scientist** 1994-2007/Jul W1
(c) 2007 Reed Business Information Ltd. All rights reserved.

[File 370] **Science** 1996-1999/Jul W3
(c) 1999 AAAS. All rights reserved.
**File 370: This file is closed (no updates). Use File 47 for more current information.*

[File 399] **CA SEARCH(R)** 1967-2007/UD=14702
(c) 2007 American Chemical Society. All rights reserved.
**File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.*

[File 434] **SciSearch(R) Cited Ref Sci** 1974-1989/Dec
(c) 2006 The Thomson Corp. All rights reserved.

[File 444] **New England Journal of Med.** 1985-2007/Jun W4
(c) 2007 Mass. Med. Soc. All rights reserved.

[File 467] **ExtraMED(tm)** 2000/Dec
(c) 2001 Informania Ltd. All rights reserved.

[File 654] **US PAT.FULL.** 1976-2007/JUN 28
(c) Format only 2007 Dialog. All rights reserved.
**File 654: IPCR/8 classification codes now searchable in 2006 records. For information about IC= index changes, see HELP NEWSIPCR.*

<!--StartFragment-->RESULT 11

ABB50295

ID ABB50295 standard; protein; 180 AA.

XX

AC ABB50295;

XX

DT 08-FEB-2002 (first entry)

XX

DE Bone marrow stromal antigen (BST-2) ovarian tumour marker protein, #80.

XX

KW Ovarian tumour marker gene; human; overexpression; upregulation;
 KW epithelial tumour; cancer; diagnosis; prognosis; disease monitoring;
 KW identification; serous cystadenoma; borderline serous tumour;
 KW serous cystadenocarcinoma; mucinous cystadenocarcinoma;
 KW mucinous cystadenoma; borderline mucinous tumour; endometrioid carcinoma;
 KW undifferentiated carcinoma; clear cell adenocarcinoma; cystadenofibroma;
 KW adenofibroma; Brenner tumour; serial analysis of gene expression; SAGE;
 KW immune response pathway; cell proliferation regulation; protein folding;
 KW membrane localised; secreted; therapeutic target; cytostatic;
 KW gene therapy; vaccine.

XX

OS Homo sapiens.

XX

PN WO200175177-A2.

XX

PD 11-OCT-2001.

XX

PF 03-APR-2001; 2001WO-US010947.

XX

PR 03-APR-2000; 2000US-0194336P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Morin PJ, Sherman-Baust CA, Pizer ES, Hough CD;

XX

DR WPI; 2001-626450/72.

DR

N-PSDB; ABA83121.

XX

PT Detecting and identifying ovarian tumor, identifying increased risk for
 PT developing ovarian cancer, and determining effectiveness of ovarian
 PT cancer treatment, by measuring expression level of ovarian tumor marker
 PT gene.

XX

PS Claim 23; Page 124; 140pp; English.

XX

CC The invention relates to methods for diagnosing and prognosing ovarian
 CC tumours in an individual via the detection and measurement of the
 CC expression of ovarian tumour marker genes (ABA83081-ABA83122, ABA83180,
 CC ABA83182 and ABA83184) or segments thereof (ABA83123-ABA83169, ABA83179,
 CC ABA83181 and ABA83183). The methods of the invention are useful for
 CC detecting an ovarian tumour in a patient, for identifying an individual
 CC at increased risk for developing ovarian cancer, in prognostic tests for
 CC assessing the relative severity of ovarian cancer, in tests for
 CC monitoring a patient in remission from ovarian cancer and in tests for
 CC monitoring disease status in a patient being treated for ovarian cancer.
 CC The methods can additionally be used to identify a particular tumour as
 CC being an ovarian tumour (i.e., an epithelial ovarian tumour selected from
 CC serous cystadenoma, borderline serous tumour, serous cystadenocarcinoma,
 CC mucinous cystadenoma, borderline mucinous tumour, mucinous
 CC cystadenocarcinoma, endometrioid carcinoma, undifferentiated carcinoma,
 CC clear cell adenocarcinoma, cystadenofibroma, adenofibroma and Brenner

CC tumour. The ovarian tumour marker genes of the invention were identified
CC using SAGE (serial analysis of gene expression) and were found to be
CC overexpressed in a broad variety of ovarian epithelial tumour cells
CC relative to normal ovarian epithelial cells. The marker genes are
CC implicated in immune response pathways, in the regulation of cell
CC proliferation and in protein folding, and many of these are membrane-
CC localised or secreted. In addition to their use as diagnostic and
CC prognostic markers, the ovarian tumour marker genes or their encoded
CC proteins may be used as therapeutic targets for the treatment and
CC prevention of ovarian cancer. Sequences ABB50257-ABB50299 represent
CC proteins encoded by ovarian tumour marker genes of the invention

XX

SQ Sequence 180 AA;

Query Match 100.0%; Score 889; DB 4; Length 180;
Best Local Similarity 100.0%; Pred. No. 2.2e-77;
Matches 180; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAV 60
        |||
Db      1 MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAV 60

Qy     61 MECRNVTLLQQLTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEI 120
        |||
Db     61 MECRNVTLLQQLTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEI 120

Qy    121 TTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ 180
        |||
Db    121 TTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ 180
```

<!--EndFragment-->